| VIVUS, Inc. Q1 2010 Earnings Call Transcript VIVUS, Inc. (VVUS)Q1 2010 Earnings CallMay 3, 2010 4:30 PM ESTComplete Story » seekingalpha.com |
Exelixis: Finding Opportunity in a Bottomed Stock Prohost Biotech submits:Following Exelixis (EXEL) press release, which announced that it has regained full rights from Bristol-Myers Squibb (BMY) to its cancer drug XL184, the firm’s stock plummeted. In the press release, Exelixis stated that BMY’ priorities made it difficult for BMY to align on the scope, breadth and pace of the ongoing clinical development of XL184 as agreed upon in the original agreement. Those who instigated the sell-off did not buy Exelixis’ explanation and were more comfortable with the notion that BMY decided to walk away from XL184, probably because of bad news about the drug. Their reasoning was that a giant pharmaceutical company like BMY, which focuses on building an impressive advanced oncology pipeline would not let a promising multi-targeted cancer drug in late phase trials slip from its hands without a significant reason. BMY did not allude to any bad reason or any reason at all for its decision. It did not comment on Exelixis’ explanation and did not deny it. Although investors’ speculation and their spontaneous response, instigating the selling of the stock, are not irrational, they were not supported by evidence-based knowledge, or facts. Their best speculation was that if BMY doubts the drug’s promises, the least of what they can do is the same as BMY did, i.e., abandoning investing in Exelixis. The sell-off was triggered by a pyramid of suppositions that have no concrete proof. Complete Story » seekingalpha.com |
DNA-Test Results Mislead Consumers, Says U.S. Genetic-testing companies that promised to help consumers understand their health risks instead offered contradictory and misleading results, government investigators said. online.wsj.com |
ERT to Present at UBS Global Life Sciences Conference on September 20, 2010 [PR Newswire] - ERT , announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive Vice President and CFO, are scheduled to present at UBS Global Life Sciences Conference at 11:30 AM EDT on September 20, 2010 in New York City, New York. us.rd.yahoo.com |
Arena Pharmaceuticals: Investors Smell a Rat Pharmalot submits: Last month, an FDA advisory committee voted 9-to-5 that the risks of the Lorqess diet drug developed by Arena Pharmaceuticals (ARNA) outweigh the benefits. That move came after concerns about valvulopathy and, in particular, links to malignancies in rats at higher doses, which were revealed in FDA briefing documents and caught some people, including Wall Street analysts, by surprise.The decision caused a stir among investors and a subsequent controversy about whether Arena properly and promptly disclosed the existence of the tumor data (look here). In comments made to Wall Street analysts following the FDA panel vote, CEO Jack Lief insisted the info was handled correctly. An FDA decision is expected later this month.Complete Story » seekingalpha.com |